Stockscreener 앱 받기
15.37
2.47%
-0.39
시간 외 거래:
15.64
0.27
+1.76%
전일 마감가:
$15.76
열려 있는:
$15.68
하루 거래량:
1.14M
Relative Volume:
0.95
시가총액:
$1.31B
수익:
-
순이익/손실:
$-230.32M
주가수익비율:
-4.3592
EPS:
-3.5259
순현금흐름:
$-196.04M
1주 성능:
-5.99%
1개월 성능:
-19.19%
6개월 성능:
-15.55%
1년 성능:
-72.50%
1일 변동 폭
$15.23
$15.69
1주일 범위
$15.23
$16.86
52주 변동 폭
$5.95
$62.75
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Company Profile
명칭
Moonlake Immunotherapeutics
전화
41 41 510 8022
주소
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
15.37 | 1.35B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
문레이크 이뮤노테라퓨틱스 Stock (MLTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-23 | 업그레이드 | Wolfe Research | Underperform → Outperform |
| 2026-03-19 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2026-01-09 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2025-11-03 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-09-30 | 다운그레이드 | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-09-29 | 다운그레이드 | Jefferies | Buy → Hold |
| 2025-09-29 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2025-07-28 | 개시 | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-11-05 | 재개 | Wedbush | Outperform |
| 2024-08-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-11-02 | 개시 | Stifel | Buy |
| 2023-09-14 | 다운그레이드 | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 개시 | Needham | Buy |
| 2023-06-15 | 개시 | Barclays | Equal Weight |
| 2023-05-01 | 개시 | Guggenheim | Buy |
| 2023-03-22 | 개시 | Wedbush | Outperform |
| 2023-03-09 | 개시 | BTIG Research | Buy |
| 2023-02-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 개시 | Bryan Garnier | Buy |
| 2022-11-11 | 개시 | Jefferies | Buy |
| 2022-08-25 | 개시 | SVB Leerink | Outperform |
| 2022-07-21 | 개시 | H.C. Wainwright | Buy |
| 2022-07-07 | 개시 | Cowen | Outperform |
모두보기
문레이크 이뮤노테라퓨틱스 주식(MLTX)의 최신 뉴스
MoonLake reports positive phase 3 psoriatic arthritis trial results By Investing.com - Investing.com Nigeria
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits
Deep Track Capital, LP Expands MoonLake Immunotherapeutics (MLTX) Stake With 1.59 Million Share Purchase - GuruFocus
MoonLake (MLTX) Quarterly Figures: Profit Per Share Falls Below Its Benchmark in the Available Record; Closing Move - Vinanet
Lost Money on MoonLake Immunotherapeutics (MLTX)? Urged to Join C - The National Law Review
MoonLake (MLTX) Financial Results: EPS Does Not Reach the Reported Estimate; After Results: Shares Finish 5.97% Lower on the DayEarnings Recovery Stocks - vinanet.vn
Class Action Alert: Levi & Korsinsky Reminds MoonLake (MLTX) Investors of December 15, 2025 Deadline - The National Law Review
Why is MoonLake Immunotherapeutics stock plunging today? - Investing.com Nigeria
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ - Stocktwits
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites - Stocktwits
MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week - Stocktwits
Why Did MLTX Stock Rise After-Hours Today? - Stocktwits
Dimensional Fund Advisors LP Has $490,000 Position in MoonLake Immunotherapeutics $MLTX - marketbeat.com
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake - Stock Titan
T. Rowe Price (MLTX holder) discloses 5.3% MoonLake Immunotherapeutics position - Stock Titan
Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A - Stock Titan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $50 - Moomoo
MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital - The Globe and Mail
MLTX LAWSUIT ALERT: Levi & Korsinsky Notifies MoonLake Immunother - The National Law Review
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study - Sahm
Avoiding Lag: Real-Time Signals in (MLTX) Movement - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.3%Time to Sell? - MarketBeat
MoonLake’s Sonelokimab Meets Primary Endpoint in Phase 3 PsA Trial - The Dermatology Digest
MoonLake’s nanobody boosts PsA indication hopes after Phase III success - Yahoo
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
A Quick Look at Today's Ratings for MoonLake Immunotherapeutics(MLTX.US), With a Forecast Between $30 to $34 - Moomoo
MoonLake's nanobody clears Phase III test, but shares slip - The Pharma Letter
MoonLake Immunotherapeutics (MLTX) Stock Analysis: 61% Upside Potential Amid Biotech Innovations - DirectorsTalk Interviews
Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate? - STAT
How Psoriatic Arthritis Trial Success and Q2 Losses Could Shape MoonLake Immunotherapeutics (MLTX) Investors - simplywall.st
MoonLake touts Phase III PsA data, but investors may have wanted more - FirstWord Pharma
Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed - TradingView
Why is MoonLake Immunotherapeutics stock plunging today? By Investing.com - Investing.com India
MoonLake Immunotherapeutics Releases Q2 2026 Financial Results - AlphaStreet
What's Going On With MoonLake Stock Monday?MoonLake (NASDAQ:MLTX) - Benzinga
MoonLake's sonelokimab meets all endpoints in Phase 3 IZAR-1 psoriatic arthritis trial - Dealroom
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's What Happened - MarketBeat
Moomoo AI Day 7 (Aug'26)Moonlake Immunotherapeutic (MLTX.US) R&D expenses and cash on hand - Moomoo
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win - Endpoints News
Traders Buy Large Volume of MoonLake Immunotherapeutics Call Options (NASDAQ:MLTX) - MarketBeat
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial - Fierce Biotech
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial - dermatologytimes.com
MoonLake Immunotherapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Cash Reserves - Kalkine Media
MoonLake Immunotherapeutics Announces Q2 2026 Financial Results and Positive Phase 3 IZAR-1 Trial Data for Sonelokimab in Psoriatic Arthritis - Kalkine Media
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals - Moomoo
MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
MoonLake Immunotherapeutics 2Q 2026: Net loss $(61.8)M, EPS $(0.84) — 10-Q Summary - TradingView
MoonLake Immunotherapeutics (MLTX) deepens loss but ends H1 2026 with $537M cash and key Phase 3 wins - Stock Titan
문레이크 이뮤노테라퓨틱스 (MLTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
문레이크 이뮤노테라퓨틱스 주식 (MLTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Reich Kristian | Chief Scientific Officer |
Jul 21 '26 |
Sale |
20.02 |
50,000 |
1,001,000 |
2,714,746 |
| Reich Kristian | Chief Scientific Officer |
Jul 22 '26 |
Sale |
20.00 |
2,448 |
48,960 |
2,712,298 |
| Reich Kristian | Chief Scientific Officer |
Jul 20 '26 |
Sale |
20.09 |
43,700 |
877,933 |
2,764,746 |
| Reich Kristian | Chief Scientific Officer |
Jul 15 '26 |
Sale |
20.01 |
16,105 |
322,261 |
2,808,446 |
0.00%
3.22%
자본화:
|
볼륨(24시간):